Figure S5. Venetoclax and JIB-04... | Rockefeller University Press

Figure S5.

Venetoclax and JIB-04 treatment in lymphoma cells with BIM and BIK deficiency. (A) Bar graph representing JIB-04 IC50 values in cell lines with or without mutations in KMT2D after 72 h of JIB-04 treatment. Each bar represents the mean ± SD of two independent experiments, each time in triplicate (n = 3). (B) Dot plot comparing JIB-04 IC50 values in cell lines with or without mutations in KMT2D. Each dot represents the mean of two independent experiments, each time in triplicate. Cell viability was measured by CellTiter-Glo assay. P values were calculated by Student’s t test. ****P < 0.0001. (C) IC50 curves at 72 h of JIB-04 in OCI-LY8; sgLacZ or OCI-LY8; sgSETD1B single-cell clones. Results were represented as mean ± SD (n = 3). (D) Western blot analysis detection of the siRNA knockdown efficiency of BIK and BIM in OCI-LY19;sgSETD1B. β-Tubulin was used as the loading control. Data representative of two independent experiments are shown. MW, molecular weight in kD. (E) Bar graph showing the percentage of cell viability in OCI-LY19;sgSETD1B cells transfected with Control-siRNA, BIK-siRNA (2 μM), and BIM-siRNA (3 μM) after 72 h treatment with Venetoclax, JIB-04, or the combination of both compounds. Cell growth was assayed using the CellTiter-Glo Luminescent Cell Viability Assay Kit. Results were represented as mean ± SD (n = 3). P values were calculated by two-way ANOVA followed by Tukey’s multiple comparisons test, ***P = 0.007, n = 3. (F) Bar graph showing the percentage of cell viability in OCI-LY19;sgSETD1B cells transfected with Control-siRNA, BIK-siRNA (2 nM), or BIM-siRNA (3 nM) after 72 h treatment with Venetoclax, JIB-04, or the combination of both compounds. Cell growth was assayed using the CellTiter-Glo Luminescent Cell Viability Assay Kit. Results were represented as mean ± SD (n = 3). P values were calculated by two-way ANOVA followed by Tukey’s multiple comparisons test, ****P < 0.0001; n.s.: non-significant; n = 3. Source data are available for this figure: SourceData FS5.

Venetoclax and JIB-04 treatment in lymphoma cells with BIM and BIK deficiency. (A) Bar graph representing JIB-04 IC₅₀ values in cell lines with or without mutations in KMT2D after 72 h of JIB-04 treatment. Each bar represents the mean ± SD of two independent experiments, each time in triplicate (n = 3). (B) Dot plot comparing JIB-04 IC₅₀ values in cell lines with or without mutations in KMT2D. Each dot represents the mean of two independent experiments, each time in triplicate. Cell viability was measured by CellTiter-Glo assay. P values were calculated by Student’s t test. ****P < 0.0001. (C) IC₅₀ curves at 72 h of JIB-04 in OCI-LY8; sgLacZ or OCI-LY8; sgSETD1B single-cell clones. Results were represented as mean ± SD (n = 3). (D) Western blot analysis detection of the siRNA knockdown efficiency of BIK and BIM in OCI-LY19;sgSETD1B. β-Tubulin was used as the loading control. Data representative of two independent experiments are shown. MW, molecular weight in kD. (E) Bar graph showing the percentage of cell viability in OCI-LY19;sgSETD1B cells transfected with Control-siRNA, BIK-siRNA (2 μM), and BIM-siRNA (3 μM) after 72 h treatment with Venetoclax, JIB-04, or the combination of both compounds. Cell growth was assayed using the CellTiter-Glo Luminescent Cell Viability Assay Kit. Results were represented as mean ± SD (n = 3). P values were calculated by two-way ANOVA followed by Tukey’s multiple comparisons test, ***P = 0.007, n = 3. (F) Bar graph showing the percentage of cell viability in OCI-LY19;sgSETD1B cells transfected with Control-siRNA, BIK-siRNA (2 nM), or BIM-siRNA (3 nM) after 72 h treatment with Venetoclax, JIB-04, or the combination of both compounds. Cell growth was assayed using the CellTiter-Glo Luminescent Cell Viability Assay Kit. Results were represented as mean ± SD (n = 3). P values were calculated by two-way ANOVA followed by Tukey’s multiple comparisons test, ****P < 0.0001; n.s.: non-significant; n = 3. Source data are available for this figure: SourceData FS5.